20 LATEST RESOURCES (55 INDEXED)
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial · January 2023
Multimedia (Interviews-Authors)
Journal of the American Medical Association
Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients with Treatment-Resistant Depression · September 2022
Multimedia (Interviews-Authors)
JAMA Psychiatry
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients with Alcohol Use Disorder: A Randomized Clinical Trial · August 2022
Multimedia (Interviews-Authors)
JAMA Psychiatry
Augmenting Computerized Cognitive Training with Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial · March 2020
Multimedia (Interviews-Authors)
American Journal of Psychiatry
A Single Ketamine Infusion Combined with Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial · December 2019
Multimedia (Interviews-Authors)
American Journal of Psychiatry
Preventing Homeless Deaths: Low Barrier Buprenorphine and Other Practical Harm Reduction · July 2019
Multimedia (Lectures-Conferences)
University of California
Crossing the Goal Line: Bringing Ketamine Treatments to the Clinic · May 2019
Multimedia (Lectures-Conferences)
Brain and Behavior Research Foundation
Ketamine: From Mechanism to Clinical Translational Delivery · April 2019
Multimedia (Lectures-Conferences)
YouTube>Semel Institute for Neuroscience and Human Behavior
Esketamine: A New Paradigm for Treatment-Resistant Depression · April 2019
Multimedia (Lectures-Conferences)
University of Connecticut
Efficacy and Safety of a Monthly Buprenorphine Depot Injection for Opioid Use Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial · February 2019
Multimedia (Interviews-Research)
Lancet
Ketamine in Treatment-Resistant Depression · February 2019
Multimedia (Lectures-Conferences)
University of Nebraska
The Benefit of Minocycline on Negative Symptoms of Schizophrenia in Patients with Recent-Onset Psychosis (BeneMin): A Randomised, Double-Blind, Placebo-Controlled Trial · October 2018
Multimedia (Interviews-Research)
Lancet Psychiatry
Medication Assisted Psychotherapy for PTSD: Focus on Ketamine and MDMA (Meetings-Events) · October 2018
Multimedia (Lectures-Conferences)
European College of Neuropsychopharmacology
Cariprazine, the New Broad Spectrum Antipsychotic: Clinical Data of Schizophrenia, Bipolar Mania, Bipolar Depression and Major Depression Studies (Meetings-Events) · October 2018
Multimedia (Lectures-Conferences)
European College of Neuropsychopharmacology
Preclinical and Clinical Findings Suggest that Evenamide Improves Symptoms in Patients with Schizophrenia through Glutamatergic Modulation (Meetings-Events) · October 2018
Multimedia (Lectures-Conferences)
European College of Neuropsychopharmacology
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism · August 2018
Multimedia (Interviews-Research)
American Journal of Psychiatry
Influence of Dose, Gender, and Cigarette Smoking on Clozapine Plasma Concentrations · June 2018
Multimedia (Interviews-Research)
Neuropsychiatric Disease and Treatment
Ketamine: Why Now? How? Where Do We Go from Here? · June 2018
Multimedia (Lectures-Conferences)
Brain and Behavior Research Foundation
Treatment Patterns, Health Care Resource Utilization, and Costs in Japanese Adults with Attention-Deficit Hyperactivity Disorder Treated with Atomoxetine · February 2018
Multimedia (Interviews-Research)
Neuropsychiatric Disease and Treatment
Safety and Effectiveness of Rapid-Acting Intramuscular Olanzapine for Agitation Associated with Schizophrenia: Japan Postmarketing Surveillance Study · January 2018
Multimedia (Interviews-Research)
Neuropsychiatric Disease and Treatment